Given that both anti-CD20 mAb20 and R848 therapy35, 36 can prime Th1 immune responses through NK cell-mediated IFNγ release and production of IL-12 by dendritic cell, and that TLR7 agonism37, 38 leads to direct induction of CD4 T-cell proliferation and stimulation of CD4 T cells through activation of antigen-presenting cell, it is likely that obinutuzumab and R848 act in synergy to activate tumor-specific CD4+ T cells. Here, TLR7 is linked to neoplasm.